Literature DB >> 6224683

Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage.

M Eandi, I Viano, F Di Nola, L Leone, E Genazzani.   

Abstract

The pharmacokinetics of norfloxacin were studied in six healthy volunteers, and three patients each with moderate renal and hepatic damage. A new specific and sensitive high performance liquid chromatography method was set up to measure plasma and urine concentrations of norfloxacin. The mean urinary concentrations after a single oral dose of 400 mg norfloxacin exceeded many times the MIC and MBC values of most of the bacterial strains responsible for urinary tract infections. Results in the patients with hepatic and renal damage indicated slight and not statistically significant differences in comparison with healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6224683     DOI: 10.1007/bf02029528

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  9 in total

1.  Norfloxacin and the antibacterial gamma pyridone beta carboxylic acids.

Authors:  S W Newsom; J Matthews; M Amphlett; R E Warren
Journal:  J Antimicrob Chemother       Date:  1982-07       Impact factor: 5.790

2.  Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae.

Authors:  M Y Khan; Y Siddiqui; R P Gruninger
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

3.  Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.

Authors:  H H Gadebusch; D L Shungu; E Weinberg; S K Chung
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

4.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

5.  In vitro antibacterial activity of norfloxacin (MK-0366).

Authors:  A King; C Warren; K Shannon; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

6.  Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates.

Authors:  M Y Khan; R P Gruninger; S M Nelson; R E Klicker
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

7.  Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography.

Authors:  V K Boppana; B N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

8.  In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

9.  Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.

Authors:  K Hirai; A Ito; Y Abe; S Suzue; T Irikura; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

  9 in total
  26 in total

Review 1.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

2.  Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800-mg oral dose.

Authors:  H Hofbauer; K G Naber; M Kinzig-Schippers; F Sörgel; C Rustige-Wiedemann; B Wiedemann; A Reiz; M Kresken
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

Review 3.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

4.  Quantitative determination of ofloxacin, ciprofloxacin, norfloxacin and pefloxacin in serum by high pressure liquid chromatography.

Authors:  A J Groeneveld; J R Brouwers
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

5.  The place of quinolones in antibacterial therapy in hospitals.

Authors:  R P Mouton
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

6.  Chronic dose urinary and serum pharmacokinetics of norfloxacin in the elderly.

Authors:  J G Kelly; N B Deaney; J Lavan; J Noel
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

7.  In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.

Authors:  J D Gay; D R DeYoung; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

8.  Ofloxacin pharmacokinetics in renal failure.

Authors:  J P Fillastre; A Leroy; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

Review 9.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; D M Richards
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

10.  Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.

Authors:  J A Hoogkamp-Korstanje
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.